All In Biotech

Drug Trial Radar · NCT06328608

A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease

Multi-centre, Open-label Trial to Assess the saFety, Pharmacodynamics, Efficacy and Pharmacokinetics of pegunigaLsidase Alfa in Patients From 2 Years to Less Than 18 Years of Age With Confirmed FabrY Disease

Last checked: Nov 20, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

22

Planned (sponsor's estimate)

Start

Jul 29, 2025

Primary completion

Oct 2028

Study completion Apr 2031

Sponsor

Lead sponsor
Chiesi Farmaceutici S.p.A.Industry
Sponsor type
Industry
Collaborators
ICON plc
First posted
Mar 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents with Fabry Disease.

Conditions

  • Fabry Disease

Interventions

  • PRX-102 1 mg/kg every two weeksDrug

    Drug: PRX-102 1 mg/kg every two weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment Emergent Adverse Events (TEAEs)Time frame: 12 Months
  2. Incidence of Infusion Related Reactions (IRRs)Time frame: 12 Months
  3. Incidence of Injection site reactions (ISRs)Time frame: 12 Months
  4. Change in Tanner stageTime frame: Baseline and 12 Months
  5. Change from baseline of 12-lead ECG quantitative parameters: Mean Heart RateTime frame: Baseline and 12 Months
  6. Change from baseline of 12-lead ECG quantitative parameters: PR IntervalTime frame: Baseline and 12 Months
  7. Change from baseline of 12-lead ECG quantitative parameters: QRS DurationTime frame: Baseline and 12 Months
  8. Change from baseline of 12-lead ECG quantitative parameters: QT IntervalTime frame: Baseline and 12 Months
  9. Change from baseline of 12-lead ECG quantitative parameters: QTc IntervalTime frame: Baseline and 12 Months
  10. Change from baseline of 12-lead ECG quantitative parameters: ST SegmentTime frame: Baseline and 12 Months
  11. Incidence of treatment-emergent Anti-Drug Antibodies (ADAs)Time frame: Baseline and 12 Months
  12. Incidence of premedication use at each visit and change of infusion premedications from baselineTime frame: Baseline and 12 Months
  13. Pharmacokinetics: Time to maximum plasma concentration (tmax)Time frame: Stage I - Baseline, week 2, week 4, week 12, week 26 and week 52; Stage II -Baseline, week 12, week 26 and week 52]
  14. Pharmacokinetic : Area under the plasma concentration-time curve from time 0 to time t (AUC0 t)Time frame: Stage I - Baseline, week 2, week 4, week 12, week 26 and week 52; Stage II -Baseline, week 12, week 26 and week 52]
  15. Pharmacokinetics: Area under the curve from time 0 to 2 weeks (AUC0-2wk)Time frame: Stage I - Baseline, week 2, week 4, week 12, week 26 and week 52; Stage II -Baseline, week 12, week 26 and week 52]
  16. Pharmacokinetics: Area under the curve from time 0 to infinity (AUC0-∞)Time frame: Stage I - Baseline, week 2, week 4, week 12, week 26 and week 52; Stage II -Baseline, week 12, week 26 and week 52]
  17. Pharmacokinetics: Terminal half-life (t1/2)Time frame: Baseline, week 2, week 4, week 12, week 26 and week 52]
  18. Pharmacokinetics: Area under the curve over a dosing interval (AUCτ)Time frame: Baseline, week 2, week 4, week 12, week 26 and week 52; Stage II -Baseline, week 12, week 26 and week 52]
  19. Pharmacokinetics: Observed drug concentration at the end of the dosing interval (Cτ)Time frame: Stage I - Baseline, week 2, week 4, week 12, week 26 and week 52; Stage II -Baseline, week 12, week 26 and week 52]
  20. Pharmacokinetics: Clearance (Cl)Time frame: Stage I - Baseline, week 2, week 4, week 12, week 26 and week 52; Stage II -Baseline, week 12, week 26 and week 52]
  21. Pharmacokinetics: Volume of distribution (Vz)Time frame: Stage I - Baseline, week 2, week 4, week 12, week 26 and week 52; Stage II -Baseline, week 12, week 26 and week 52]
  22. Change in eGFRTime frame: Baseline and 12 Months
  23. Change in annualized eGFR slopeTime frame: Baseline and 12 Months
  24. Change in urine albumin levelsTime frame: Baseline and 12 Months
  25. Change in urine protein levelsTime frame: Baseline and 12 Months
  26. Change from baseline in LVMi as assessed by echocardiogramTime frame: Baseline and 12 Months
  27. Change from baseline in LVMi as assessed by echocardiogramTime frame: Baseline and 12 Months
  28. Change from baseline in LVMi as assessed by echocardiogramTime frame: Baseline and 12 Months
  29. Change from baseline in LVMi as assessed by echocardiogramTime frame: Baseline and 12 Months
  30. Change from baseline in LVMi as assessed by echocardiogramTime frame: Baseline and 12 Months
  31. Incidence of any cardiac arrythmias as assessed by Holter ECGTime frame: Baseline and 12 Months
  32. Change in plasma levels of cardiac biomarkersTime frame: Baseline and 12 Months
  33. Change in plasma level of Gb3 concentration (nM)Time frame: Baseline and 12 Months
  34. Change in plasma level of lyso-Gb3 (nM)Time frame: Baseline and 12 Months
  35. Change in urine level of lyso-Gb3 (nM)Time frame: Baseline and 12 Months
  36. Incidence of change from baseline in the number of different pain medicationsTime frame: Baseline and 12 Months
  37. Incidence of Fabry Clinical EventsTime frame: 12 Months
  38. Change from baseline of Mainz Severity Score Index (MSSI) scoresTime frame: Baseline and 12 Months
  39. Change from baseline of PedsQL-GI (or GSRS for subjects who reaches 18 yrs of age) scoresTime frame: Baseline and 12 Months
  40. Change from baseline of FPHPQ scoresTime frame: Baseline and 12 Months
  41. Change from baseline of PedsQL-PPQ (or BPI-SF for subjects who reaches 18 yrs of age) scoresTime frame: Baseline and 12 Months
  42. Change from baseline of EQ-5D-Y (or EQ-5D-5L for subjects who reaches 18 yrs of age) scoresTime frame: Baseline and 12 Months

Locations

12 sites in 6 countries. Site status is shown where the registry gives one.

  • Phoenix Children's

    Phoenix, Arizona · Recruiting

  • Emory Genetics Clinical Trials Center

    Atlanta, Georgia · Recruiting

  • University of Iowa

    Iowa City, Iowa · Recruiting

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio · Recruiting

  • University of Utah

    Salt Lake City, Utah · Recruiting

  • Lysosomal and Rare Disorders Research and Treatment Center Inc

    Fairfax, Virginia · Recruiting

  • UK für Kinder- und Jugendheilkunde der PMU Salzburg

    Salzburg, Austria · Recruiting

  • Centre Hospitalier Universitaire (CHU) de Bordeaux - Groupe Hospitalier Pellegrin

    Bordeaux, France · Recruiting

  • Hopital Arnaud de Villeneuve

    Montpellier, France · Recruiting

  • Haukeland Universitetssjukehus

    Bergen, Norway · Recruiting

  • Hospital Clinico Universitario De Santiago De Compostela

    Santiago de Compostela, Spain · Recruiting

  • Great Ormond Street Hospital for Children NHS Foundation Trust

    London, United Kingdom · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.